Dr. Arvind Chaudhry, MD
Hematology & Oncology (Hematology & Oncology Physician)
6001 North Mayfair, Medical Oncology Associates Ps.
Spokane, WA 99208
Who else practices at this address →
Spokane County includes primary care (67% of residents) and dental (43% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 972
Licensed in Washington since 1999, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD00037930 (first issued 1999; active) -
Specialist
WA license MD00037930 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prov Sacred Hrt Med Ctr & Childs Hosp. Spokane, WA
- Deaconess Medical Center Spokane, WA
- Bonner General Hospital Sandpoint, ID
- Providence Mount Carmel Hospital Colville, WA
- Boundary Community Hospital Bonners Ferry, ID
Medical groups
- Medical Oncology Associates Ps (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 972
- Services billed
- 299,162
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 44,000 | 46 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 16,022 | 120 |
| Injection, aprepitant, 1 mg | 15,210 | 34 |
| Injection, denosumab, 1 mg | 14,700 | 63 |
| Injection, docetaxel, 1 mg | 5,226 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,784 | 72 |
| Injection, palonosetron hcl, 25 mcg | 2,790 | 55 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,525 | 703 |
| Established patient office or other outpatient visit, 20-29 minutes | 2,450 | 776 |
| Insertion of needle into vein for collection of blood sample | 2,277 | 710 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Spokane, WA | 202 |
| Prednisone Other prescribers in Spokane, WA | 115 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Spokane, WA | 94 |
| Imbruvica (ibrutinib) | 90 |
| Oxycodone Hcl Other prescribers in Spokane, WA | 87 |
| Hydroxyurea Other prescribers in Spokane, WA | 79 |
| Letrozole Other prescribers in Spokane, WA | 77 |
| Eliquis (apixaban) Other prescribers in Spokane, WA | 75 |
| Brukinsa (zanubrutinib) | 54 |
| Acyclovir Other prescribers in Spokane, WA | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 58 companies reported 290 payments worth $11,320 in total to this clinician.
| Exelixis Inc. | $4,470 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,510 |
| Janssen Biotech, Inc. | $482 |
| Merck Sharp & Dohme LLC | $476 |
| Pfizer Inc. | $345 |
| AstraZeneca Pharmaceuticals LP | $282 |
| E.r. Squibb & Sons, L.l.c. | $228 |
| Tersera Therapeutics LLC | $227 |
| Food and Beverage | $5,828 |
|---|---|
| Honoraria | $2,700 |
| Long term medical supply or device loan | $1,164 |
| Travel and Lodging | $1,135 |
| Education | $493 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Sep 18, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,700 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $597 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $293 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $125 |
| Seagen Inc. Sep 22, 2025 | Education in-kind | $99.95 |
| Seagen Inc. Jan 6, 2025 | Education in-kind | $99.95 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Janssen Biotech, Inc. Dec 3, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $96.00 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Seagen Inc. Sep 22, 2025 | Education in-kind | $99.95 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Exelixis Inc. Sep 18, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,700 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $597 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $293 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $125 |
| Exelixis Inc. Sep 6, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA · in-kind | $70.00 |
| Exelixis Inc. Sep 5, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA | $30.52 |
| Exelixis Inc. Sep 5, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Redondo Beach, CA | $20.00 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Genentech, Inc. Jul 21, 2025 | Education Tecentriq · BioOncology · in-kind | $53.45 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Janssen Biotech, Inc. Apr 22, 2025 | Education RYBREVANT · Oncology · in-kind | $99.00 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Astellas Pharma US Inc Jan 8, 2025 | Education in-kind | $44.99 |
| Seagen Inc. Jan 6, 2025 | Education in-kind | $99.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 35 industry-funded studies in 2025, from 19 companies. The companies reported $983,886 in research payments for these studies, mostly to the institutions running them.
- A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or…
Exelixis Inc. - PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Ca…
Amgen Inc. - A Phase I, Open-label, Multicenter Study of ZL 1218 as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor…
Merck Sharp & Dohme LLC - Study name not reported
Organon Llc - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Beone Medicines Ltd. · Completed · NCT04116437 - A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell…
Exelixis Inc. - A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca UK Limited - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Recruiting · NCT05254743
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.